Skip to content

Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain

Efficacy and Safety of Opioid Rotation Compared With Opioid Dose Escalation in Patients With Moderate to Severe Cancer Pain - Open Label, Randomized, Prospective Study

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02084355
Enrollment
136
Registered
2014-03-12
Start date
2014-04-30
Completion date
2016-01-31
Last updated
2014-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Pain

Keywords

Significant cancer pain, at least numeric rating scale 4

Brief summary

Although opioid rotation is well known treatment modality in reducing pain and opioid-induced neurotoxicity, it is not established whether opioid rotation is more appropriate or opioid escalation is more effective in controlling significant pain in cancer patients under opioid medication. \- The purpose of this study is to determine effective therapy out of opioid rotation and opioid dose escalation in patients with moderate to severe cancer pain who have been already treated with strong opioid.

Interventions

DRUGoral hydromorphone

Sponsors

Gyeongsang National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age \> 18 years * patients who are being treated with one of strong opioids including oral oxycodone, oral hydromorphone, or fentanyl patch with range from 60 mg to 200 mg of oral morphine equivalent daily dose (MEDD) * moderate to severe cancer pain (numeric rating scale more than 3) at screening * patients without uncontrolled adverse effects associated with currently applied opioid

Exclusion criteria

* previous opioid rotation * unable to take oral medication * life expectancy less than a month * newly started chemotherapy and/or radiotherapy within past 2 weeks of screening * serum aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase \> 2.5 times of upper normal limit * serum total bilirubin or creatinine \> 1.5 times of upper normal limit

Design outcomes

Primary

MeasureTime frame
The rate of successful pain control defined as a 30% or 2-point reduction in the numeric rating scaleEighteen months

Countries

South Korea

Contacts

Primary ContactSe-Il Go, M.D.
gose1@hanmail.net+82 55 750 9454

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026